Mountain Crest Acquisition Strikes 72 Percent After Merging With Better Therapeutics

Mountain Crest Acquisition Corp II announced today that its stockholders approved the proposed business combination with Better Therapeutics Inc., which is focused on developing a novel form of behavioral therapy to address the underlying causes of cardiometabolic disorders. Mountain Crest gives in more and more to business ideas and strategies to make the company prosper in the market of medicine. Mountain Crest Acquisition stock surges 71% after the announcement of business partnership news. It was trading as low as $9.30 in the previous trading session. It’s now trading at $16.07 in the pre-market trading session today on November 1.

As part of the closing of the business combination, the company will change its name to Better Therapeutics, Inc. Better Therapeutics, a company focused on developing digital therapeutics for the treatment of cardiometabolic diseases, has successfully completed its acquisition of MCAD. Proceeds from the transaction will allow the company to advance its pipeline and expand its operations. Suying Liu, Chairman, and CEO of the Company commented on the partnership with Kevin O’Brien and the Better Therapeutics team. Mountain Crest Acquisition Corp. II became a reverse merger. It is focused on acquiring or merging with one or more businesses.